Spinal Muscular Atrophy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a spinal cord injury, a brainstem stroke, muscular dystrophy, ALS (Lou Gehrig's disease), or a similar condition affecting movement
- You have partial or complete loss of movement and feeling in both your arms and legs (confirm with trial site)
- You live within a three-hour drive of the study location
- There may be additional requirements to join (confirm with trial site)
Who may not be able to join:
- You have significant vision problems that make it hard to look at a computer screen for extended periods, even with glasses or contact lenses
- You regularly take steroid medications by mouth or through an IV, or take medications that lower your immune system
- You have another serious illness or condition that could make it difficult for you to take part in the study
- There may be additional reasons that could prevent participation (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Leigh R Hochberg, M.D., Ph.D., Massachusetts General Hospital
Phone: 617-724-9247
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary endpoint of this Study is to determine the safety of the BrainGate2 Neural Interface System.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.